Loading
Life sciences · Journal article
Biofilm · June 15, 2026
Encouraging direction, but not yet definitive.
This laboratory study examined biofilm formation and antibiotic susceptibility in 57 clinical Achromobacter xylosoxidans isolates using static and continuous-flow microfluidic systems. Non-CF isolates showed faster early adhesion than CF isolates, while trimethoprim-sulfamethoxazole and cefiderocol were most effective at reducing mature biofilm at 10 × MIC, and sub-inhibitory concentrations (0.5 × MIC) of some beta-lactams paradoxically enhanced biofilm formation.
Journal article. Achromobacter xylosoxidans clinical isolates from cystic fibrosis and non-cystic fibrosis patients.
Non-CF isolates displayed faster early adhesion than CF isolates, whereas mature biofilm biomass was comparable between groups Sub-inhibitory antibiotic concentrations (0.5 × MIC) elicited three distinct responses: biofilm formation enhancement (piperacillin-tazobactam, meropenem, imipenem), no effect (trimethoprim-sulfamethoxazole), or biofilm reduction (cefiderocol) Exposing mature biofilm to 10 × MIC identified trimethoprim-sulfamethoxazole and cefiderocol as the most effective agents in biofilm biomass reduction
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest that antibiotic concentrations below MIC may paradoxically enhance biofilm formation for carbapenems and piperacillin-tazobactam, while trimethoprim-sulfamethoxazole and cefiderocol show superior activity against mature biofilms. Clinicians treating A. xylosoxidans infections should consider these differential biofilm responses when selecting antibiotics, though clinical validation is required.
Comparative in vitro study using complementary static and dynamic methods reveals differential biofilm behaviors and antibiotic responses in clinical A. xylosoxidans isolates, with potential therapeutic implications.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest that antibiotic concentrations below MIC may paradoxically enhance biofilm formation for carbapenems and piperacillin-tazobactam, while trimethoprim-sulfamethoxazole and cefiderocol show superior activity against mature biofilms. Clinicians treating A. xylosoxidans infections should consider these differential biofilm responses when selecting antibiotics, though clinical validation is required.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Achromobacter xylosoxidans is an opportunistic pathogen in both cystic fibrosis (CF) and non-CF patients, in whom biofilm formation contributes to bacterial persistence and antibiotic tolerance. This study aimed to characterize early and mature biofilm formation in 57 clinical A. xylosoxidans isolates using complementary and physiologically relevant approaches and to compare biofilm phenotypes according to isolate origin (CF/non-CF). Early adhesion was assessed using the Biofilm Ring Test®, mature biofilm viable biomass was quantified under static conditions by colony-forming units counts, and biofilm dynamics were analyzed in a continuous-flow microfluidic system. The effects of five clinically relevant antibiotics (trimethoprim-sulfamethoxazole, piperacillin-tazobactam, meropenem, imipenem, and cefiderocol) were evaluated under dynamic conditions at sub-inhibitory concentrations (0.5 × Minimum Inhibitory Concentration (MIC)) and on preformed biofilm at inhibitory concentrations (10 × MIC). Non-CF isolates displayed faster early adhesion than CF isolates, whereas mature biofilm biomass was comparable between groups. If early adhesion did not predict mature biofilm biomass, dynamic biofilm coverage under flow conditions correlated with static mature biofilm levels. Sub-inhibitory antibiotic concentrations failed to prevent initial adhesion and elicited three distinct responses: biofilm formation enhancement (piperacillin-tazobactam, meropenem, imipenem), no effect (trimethoprim-sulfamethoxazole), or biofilm reduction (cefiderocol). Exposing mature biofilm to 10 × MIC identified trimethoprim-sulfamethoxazole and cefiderocol as the most effective agents in biofilm biomass reduction, whereas carbapenems and piperacillin-tazobactam were less effective. These findings provide new insights into A. xylosoxidans biofilm biology and may help guide therapeutic strategies for infections caused by this emerging, increasingly drug-resistant pathogen.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.